KIT and melanoma: Furthermore, and based on preclinical studies indicating superior activity of dasatinib among other RTKi to the most common mutation on exon 11 L576P KIT, a phase II Trial (E2607) assessed dasatinib in KIT positive melanoma patients but the trial closed early because of slow accrual and too modest responses.